Advanced Enzyme Tech
ADVENZYMES NSE
Advanced Enzyme Tech
HealthcareNSE: ADVENZYMES BSE: 540025 Biotechnology
Key Fundamentals
MicrocapBiotechnologyHealthcareMarket Cap
₹3,352 Cr
Volatility
Moderate
P/E Ratio
19.8
EBITDA
₹264 Cr
Return on Equity
10.31%
Debt to Equity
0.02
Book Value
₹145.72
EPS
₹13.3
52W High
₹419
52W Low
₹251.95
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 40.9%
Weaknesses
3- The company has delivered a poor sales growth of 8.24% over past five years.
- Company has a low return on equity of 10.3% over last 3 years.
- Promoter holding has decreased over last 3 years: -3.27%
Growth Rate
Revenue Growth
16.51% higher than
3Y
Net Income Growth
29.55% higher than
3Y
Cash Flow Change
10.02% lower than
3Y
ROE
13.05% higher than
3Y
ROCE
8.47% higher than
3Y
EBITDA Margin (Avg.)
-0.41% higher than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 147 | 158 | 161 | 158 | 155 | 146 | 169 | 167 | 186 | 185 | 172 | 203 | 190 |
| Expenses | 103 | 107 | 107 | 102 | 103 | 104 | 114 | 122 | 129 | 124 | 123 | 140 | 139 |
| Operating Profit | 44 | 51 | 54 | 55 | 51 | 42 | 55 | 46 | 56 | 60 | 49 | 63 | 51 |
| OPM % | 30% | 32% | 33% | 35% | 33% | 29% | 33% | 27% | 30% | 33% | 29% | 31% | 27% |
| Other Income | 7 | 6 | 14 | -6 | 7 | 10 | 8 | 9 | 9 | 10 | 20 | 7 | 13 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 |
| PBT | 41 | 48 | 59 | 40 | 49 | 42 | 53 | 43 | 55 | 60 | 58 | 60 | 54 |
| Tax % | 29% | 27% | 28% | 25% | 28% | 21% | 27% | 38% | 26% | 25% | 26% | 24% | 28% |
| Net Profit | 29 | 35 | 42 | 30 | 35 | 33 | 39 | 27 | 40 | 45 | 43 | 45 | 39 |
| EPS in Rs | 2.58 | 3.08 | 3.74 | 2.53 | 3.05 | 2.94 | 3.37 | 2.37 | 3.57 | 3.87 | 3.8 | 3.84 | 3.31 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 222 | 293 | 329 | 391 | 420 | 444 | 502 | 529 | 541 | 624 | 637 | 746 | 750 |
| Expenses | 131 | 155 | 177 | 226 | 236 | 241 | 269 | 327 | 382 | 418 | 441 | 515 | 526 |
| Operating Profit | 91 | 138 | 152 | 165 | 184 | 203 | 232 | 203 | 158 | 206 | 196 | 230 | 224 |
| OPM % | 41% | 47% | 46% | 42% | 44% | 46% | 46% | 38% | 29% | 33% | 31% | 31% | 30% |
| Other Income | 1 | -3 | 3 | 1 | 5 | 6 | 9 | 6 | 21 | 21 | 33 | 46 | 50 |
| Interest | 9 | 8 | 4 | 9 | 5 | 4 | 3 | 3 | 3 | 4 | 5 | 4 | 2 |
| Depreciation | 9 | 9 | 13 | 18 | 21 | 26 | 28 | 35 | 35 | 35 | 37 | 40 | 40 |
| PBT | 74 | 118 | 137 | 139 | 162 | 179 | 210 | 171 | 140 | 188 | 187 | 233 | 231 |
| Tax % | 31% | 35% | 32% | 33% | 28% | 26% | 28% | 28% | 26% | 27% | 28% | 25% | — |
| Net Profit | 51 | 77 | 93 | 94 | 116 | 133 | 151 | 124 | 104 | 137 | 134 | 174 | 172 |
| EPS in Rs | 4.6 | 6.97 | 8.2 | 8.07 | 9.95 | 11.58 | 13.09 | 10.7 | 9.45 | 11.92 | 11.72 | 15.07 | 14.82 |
| Div. Payout % | 4% | 3% | 5% | 6% | 6% | 5% | 7% | 9% | 11% | 43% | 44% | 36% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
| Reserves | 188 | 256 | 442 | 537 | 657 | 817 | 948 | 1,066 | 1,213 | 1,302 | 1,398 | 1,610 |
| Borrowings | 115 | 101 | 54 | 67 | 35 | 28 | 23 | 35 | 34 | 47 | 39 | 32 |
| Other Liabilities | 92 | 71 | 65 | 102 | 91 | 104 | 153 | 137 | 142 | 150 | 151 | 170 |
| Total Liabilities | 417 | 450 | 583 | 727 | 805 | 971 | 1,146 | 1,260 | 1,411 | 1,521 | 1,611 | 1,834 |
| Fixed Assets | 287 | 285 | 421 | 491 | 495 | 563 | 601 | 619 | 649 | 650 | 679 | 692 |
| CWIP | 5 | 7 | 8 | 11 | 10 | 10 | 10 | 15 | 22 | 41 | 22 | 51 |
| Investments | 0 | 0 | 0 | 0 | 111 | 124 | 121 | 102 | 360 | 403 | 480 | 584 |
| Other Assets | 125 | 158 | 153 | 226 | 188 | 275 | 413 | 524 | 380 | 427 | 430 | 507 |
| Total Assets | 417 | 450 | 583 | 727 | 805 | 971 | 1,146 | 1,260 | 1,411 | 1,521 | 1,611 | 1,834 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 54 | 93 | 107 | 116 | 129 | 141 | 163 | 122 | 140 | 141 | 142 | 157 |
| Investing | -15 | -10 | -60 | -60 | -124 | -43 | -27 | 2 | -286 | -65 | -89 | -72 |
| Financing | -36 | -63 | -65 | -2 | -43 | -39 | -26 | -48 | -26 | -59 | -73 | -70 |
| Net Cash Flow | 2 | 21 | -18 | 54 | -38 | 60 | 109 | 75 | -171 | 17 | -20 | 15 |
| Free Cash Flow | 42 | 88 | 97 | 105 | 116 | 90 | 143 | 95 | 102 | 94 | 108 | 105 |
| CFO/OP | 88 | 88 | 105 | 97 | 70 | 94 | 94 | 87 | 112 | 93 | 103 | 96 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 52 | 55 | 55 | 51 | 61 | 63 | 61 | 68 | 58 | 66 | 71 |
| Inventory Days | 403 | 358 | 352 | 339 | 363 | 361 | 346 | 402 | 343 | 375 | 378 | 335 |
| Days Payable | 89 | 68 | 57 | 78 | 46 | 43 | 56 | 60 | 67 | 40 | 47 | 76 |
| Cash Conversion Cycle | 374 | 342 | 351 | 315 | 369 | 379 | 353 | 404 | 344 | 393 | 397 | 331 |
| Working Capital Days | -43 | 3 | 76 | 47 | 72 | 90 | 94 | 116 | 109 | 102 | 112 | 116 |
| ROCE % | 25% | 36% | 31% | 25% | 24% | 22% | 22% | 16% | 12% | 15% | 13% | 14% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Advanced Enzyme Tech insights
65 extracted metrics + investor summaries across FY10–FY26.
Documents
2
Announcement under Regulation 30 (LODR)-Newspaper Publication
13h - Copy of newspaper publication of extract of audited consolidated financial results for quarter and year ended March 31, 2026. 13h - Copy of newspaper publication of extract of audited consolidated financial results for quarter and year ended March 31, 2026.
3
Announcement under Regulation 30 (LODR)-Change in Directorate
1d - Board approved FY26 results, recommended ₹1.35 dividend, reappointed director/auditor, and allotted 49,350 ESOP shares. 1d - Board approved FY26 results, recommended ₹1.35 dividend, reappointed director/auditor, and allotted 49,350 ESOP shares.
4
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
2d - FY26 audited results approved; final dividend ₹1.35/share, director appointments, and 49,350 ESOP shares allotted. 2d - FY26 audited results approved; final dividend ₹1.35/share, director appointments, and 49,350 ESOP shares allotted.
5
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
2d - Allotment of 49,350 Equity Shares of face value of Rs. 2/- per share pursuant to the Exercise of Options under Advanced Enzyme Technologies Limited - … 2d - Allotment of 49,350 Equity Shares of face value of Rs. 2/- per share pursuant to the Exercise of Options under Advanced Enzyme Technologies Limited - …
Frequently Asked Questions about Advanced Enzyme Tech
What does Advanced Enzyme Technologies Ltd do?
Advanced Enzyme Technologies Limited is engaged in the business of manufacturing and sales of enzymes.[1]
Where is Advanced Enzyme Technologies Ltd (ADVENZYMES) listed?
Advanced Enzyme Technologies Ltd trades as ADVENZYMES on the NSE and under code 540025 on the BSE.
Which sector does Advanced Enzyme Technologies Ltd belong to?
Advanced Enzyme Technologies Ltd is classified under the Healthcare sector, in the Biotechnology industry.
What is the market capitalisation of Advanced Enzyme Technologies Ltd?
Advanced Enzyme Technologies Ltd has a market capitalisation of ₹3,352 Cr, which places it in the Small Cap band.
What is the PE ratio of Advanced Enzyme Technologies Ltd?
Advanced Enzyme Technologies Ltd trades at a PE ratio of 19.80, on earnings per share of ₹13.3, against a book value of ₹145.72 per share.
What is the 52-week high and low of Advanced Enzyme Technologies Ltd?
Over the last 52 weeks Advanced Enzyme Technologies Ltd has traded between ₹251.95 and ₹419.
Does Advanced Enzyme Technologies Ltd pay dividends?
Advanced Enzyme Technologies Ltd has a dividend yield of 1.76%.
What is the Return on Equity (ROE) of Advanced Enzyme Technologies Ltd?
Advanced Enzyme Technologies Ltd reported a return on equity of 10.31%. Its debt-to-equity ratio is 0.02.
Company Information
Advanced Enzyme Technologies Limited is engaged in the business of manufacturing and sales of enzymes.[1]
Website advancedenzymes.com
CEO Mr. Beni Prasad Rauka CA
Employees 338
Listed 2016-08-01
Face Value ₹ 2
Issued Size 11,19,26,800
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ADVENZYMES.md for Advanced Enzyme Technologies Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.